



## Jazz Pharmaceuticals to Report 2015 Second Quarter Financial Results on August 5, 2015

July 22, 2015

DUBLIN, July 22, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2015 second quarter financial results on Wednesday, August 5, 2015, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to discuss 2015 second quarter financial results and provide a business and financial update.

Interested parties may access the live audio webcast via the Investors & Media section of the Jazz Pharmaceuticals website at [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com). Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for one week.

### **Audio webcast/conference call:**

U.S. Dial-In Number: +1 877 546 5019

International Dial-In Number: +1 857 244 7551

Passcode: 69329137

A replay of the conference call will be available through August 12, 2015 and accessible through one of the following telephone numbers, using the passcode below:

Replay U.S. Dial-In Number: +1 888 286 8010

Replay International Dial-In Number: +1 617 801 6888

Passcode: 47514310

### **About Jazz Pharmaceuticals**

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and/or product candidates with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution and Erwinaze® (asparaginase *Erwinia chrysanthemi*) in the U.S., and markets Erwinase® and Defitelio® (defibrotide) in Europe and other countries outside the U.S. For more information, please visit [www.jazzpharmaceuticals.com](http://www.jazzpharmaceuticals.com).

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2015-second-quarter-financial-results-on-august-5-2015-300117318.html>

SOURCE Jazz Pharmaceuticals plc

Investors: Kathee Littrell, Vice President, Investor Relations, Ireland, +353 1 634 7887 U.S., +1 650 496 2717; or Media: Laurie Hurley, Vice President, Corporate Affairs, Ireland, +353 1 634 7894, U.S., +1 650 496 2796